A program at UH has just gotten a rare and prestigious accreditation. Photo by Tom Fisk from Pexels

A program at the University of Houston has received a rare global accreditation that will allow for more opportunities for the students in both the graduate and undergraduate programs.

The Chartered Institute of Logistics and Transport has accredited UH's Supply Chain & Logistics Technology bachelor's and master's degree plans. Now, students can apply for membership upon graduation and use the CILT credential after their name, according to a press release from UH, and this is the first academic program in the United States to have this distinction.

"In launching our globally-recognized credential program, we are addressing gaps in skill sets and focusing on filling those gaps with our students, helping them become more marketable," says Margaret Kidd, program director of Supply Chain & Logistics Technology, in the release.

Port Houston has granted $50,000 to the program, and these funds are being used to take the curriculum digital and allow for an online platform for certificate courses.

"The College of Technology prides itself in providing degree programs that support the workforce – a workforce that both needs to expand in numbers to boost the economy, but also to provide a more relevant education for industry and commerce," says Anthony P. Ambler, dean of the UH College of Technology, in the release. "We are grateful to the Port Houston and its support of our technology program which explicitly exposes students to how business operates so that they are able to be productive quickly."

The news was announced at a press conference at UH. Harris County Commissioner for Precinct 2 Adrian Garcia and Port Houston Commissioner Wendy Montoya Cloonan joined UH representatives at the event.

"The pandemic has wrecked several sectors of the economy, directly impacting thousands, and so many are searching for new skills that translate to this new normal. This UH program, funded by Port grants, is yet another way we and our partners are addressing that," says Commissioner Garcia. "Hardworking people need locally elected officials, educational institutions, and industry to help us get past these difficult times, which is why I am extremely excited about the launch of this program."

The first group of participants for the program will come from dual-credit high schools with a logistics focus and community colleges offering logistics and international business degrees.

"Our program plays an integral part in preparing the next generation of workers. We thank Port Houston for funding our project which provides meaningful influence for area students," says Kidd.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”